FAQ: Oragenics Inc.'s $20 Million Preferred Stock and Warrant Offering

What is Oragenics Inc. announcing?

Oragenics Inc. is announcing a $20 million offering through the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, priced at $25.00 per unit.

Why is Oragenics Inc. raising $20 million?

The proceeds will support ONP-2 concussion trials, research and development, repayment of a $3 million bridge note, and general corporate needs.

How does the Preferred Stock and Warrant offering work?

Each unit consists of a share of Series H Convertible Preferred Stock and a Warrant that allows the purchase of an additional Preferred share at $25.00, with Preferred shares convertible into common stock at $2.50.

Who is acting as the placement agent for this offering?

Dawson James Securities, Inc. is acting as the sole placement agent for this offering.

When is the closing of this offering expected?

The closing of this offering is expected on or about July 2, 2025.

What is Oragenics Inc.’s focus?

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including treatments for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC).

Where can I find more information about Oragenics Inc.?

More information about Oragenics Inc. can be found on the company’s website at www.Oragenics.com or in the company’s newsroom at https://ibn.fm/OGEN.

What are the implications of this offering for investors?

This offering provides investors with an opportunity to participate in Oragenics Inc.’s growth through the purchase of convertible preferred stock and warrants, supporting the company’s development of innovative treatments for neurological disorders and infectious diseases.

How can I receive updates about Oragenics Inc.?

Updates relating to Oragenics Inc. (OGEN) are available in the company’s newsroom at https://ibn.fm/OGEN.